Categories General

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

SALT LAKE CITY, Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, sa...

Read More
Categories General

FBM KLCI Futures Lower In Early Trading

KUALA LUMPUR, The FTSE Bursa Malaysia KLCI (FBM KLCI) futures on Bursa Malaysia Derivatives were lower in early trading in line with the underlying cash market. As of 9.22 am, September 2024 fell 6.0 points to 1,654.0, October 2024 gave up 5.0 point...

Read More